

KURZPROTOKOLL ENLARGE

Öffentlicher Titel	Nicht interventionelle Studie zu Nivolumab bei lokal fortgeschrittenem oder metastasiertem NSCLC nach primärer Chemotherapie
Wissenschaftl. Titel	A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology (Stage IIIB/IV) After Prior Chemotherapy
Kurztitel	ENLARGE
Studienart	multizentrisch, Anwendungsbeobachtung, prospektiv, offen/unverblindet, einarmig, Pharma-Studie, nicht-interventionelle Studie
Studienphase	nicht zutreffend
Erkrankung	Lunge: Lungenkrebs: Nicht kleinzelliges Lungenkarzinom (NSCLC) - sonstige Studien
Einschlusskriterien	<ul style="list-style-type: none">- Histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC, Stage IIIB/Stage IV- Decision to initiate a treatment with Nivolumab for the first time already undertaken by physician- Males and Females, ≥ 18 years of age
Ausschlusskriterien	<ul style="list-style-type: none">- Current primary diagnosis of a cancer other than advanced NSCLC. Example: A cancer other than NSCLC that requires systemic or other treatment.- Pre-treatment with Nivolumab and/or Ipilimumab (pre-treatment with checkpoint-inhibitors other than Nivolumab and Ipilimumab, and Tyrosine Kinase Inhibitors(TKIs) is allowed)- Current participation in an interventional clinical trial for treatment of NSCLC. (Patients who have completed their participation in an interventional trial or who are not receiving study drug anymore and who are only followed-up for overall survival can be enrolled. For blinded studies, the treatment administered needs to be known)
Alter	18 Jahre und älter
Fallzahl	660
Prüfzentren	GPR Gesundheits- und Pflegezentrum Rüsselsheim (Rekrutierung beendet) August-Bebel Straße 59 65428 Rüsselsheim Prof. Dr. med. Dimitri Flieger Tel: 06142 881367 Fax: 06142 881280 Flieger@GP-Ruesselsheim.de St. Elisabethen-Krankenhaus (Rekrutierung beendet) Ginnheimer Str.3 60487 Frankfurt am Main Prof. Dr. med Joachim Bargon Tel: 069 79392219 Fax: 069 06979392669 j.bargon@katharina-kasper.de
Sponsor	Bristol-Myers Squibb
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT02910999
Links	Studiendokumente zum Download (roXtra)